Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P61278 (somatostatin)
 22,083 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Somatostatin release from the isolated pancreas of 3 normal and 6 streptozotocin diabetic dogs has been measured in response to various stimuli to determine whether abnormalities in somatostatin release are present in the diabetic pancreas. Simultaneous measurement of glucagon secretion was also made. In the pancreas from normal dogs increases in perfusate glucose from 25 to 200 mg/100 ml induced a 2--3 fold increase in somatostatin release and a two thirds decrease in glucagon secretion. In contrast, in the diabetic pancreas glucose caused no change in the secretion of the two hormones. In the diabetic pancreas addition of insulin to the perfusate (25,000 microU/ml) for periods from 10 to 75 minutes aimed at restoring normal extracellular insulin levels in the islets failed to restore either somatostatin or glucagon secretion to normal. In contradistinction to the lack of effect of glucose, the somatostatin and glucagon responses to arginine (5 mmol/l), isoproterenol (2 ng/ml) and calcium (5 mmol/l) were normal in the diabetic pancreas. The data suggests the presence of a selective glucoreceptor abnormality of the D as well as of B and A cells in the streptozotocin diabetic dog.
Diabetologia 1979 Dec
PMID:Streptozotocin diabetes: a glucoreceptor dysfunction affecting D cells as well as B and A cells. 39 6

In 21 female Beagle dogs an experimental pancreatitis was induced by injection of bile into the pancreatic duct system. Beside controls, dogs received 62.5 micrograms/h cyclic somatostatin (SRIF) a continuous i.v. infusion starting with a bolus of 250 micrograms 15 minutes before or 2 hours after bile injection. Following blood parameters were determined: lipase, amylase, blood count, minerals, glucose, insulin, gastrin, secretin and CCK. Two controls died within 24 hours, the others were sacrificed after 48 hours. All pancreata were examined morephologically. The controls developed all clinical signs of acute hemorrhagic pancreatitis, whereas all SRIF-treated dogs were in much better general condition. Lipase and amylase increased in all groups. In the controls insulin, gastrin and secretin remained unchanged and CCK rose slightly. SRIF-treatment diminished insulin, CCK and the test meal-induced increase of secretin. At autopsy the pancreata of the controls were nearly entirely apoplectic. The SRIF-treated dogs showed less damage of the pancreas and no severe hemorrhagic necrosis was noted. The beneficial effect of SRIF cannot only be due to an interaction with intestinal hormones. An additional direct protective effect on the exocrine parenchyma is proposed to exist.
Horm Metab Res 1979 Dec
PMID:Effect of somatostatin on bile-induced acute hemorrhagic pancreatitis in the dog. 39 59

A gene for somatostatin, a mammalian peptide (14 amino acid residues) hormone, was synthesized by chemical methods. This gene was fused to the Escherichia coli beta-galactosidase gene on the plasmid pBR322. Transformation of E. coli with the chimeric plasmid DNA led to the synthesis of a polypeptide including the sequence of amino acids corresponding to somatostatin. In vitro, active somatostatin was specifically cleaved from the large chimeric protein by treatment with cyanogen bromide. This represents the first synthesis of a functional polypeptide product from a gene of chemically synthesized origin.
Science 1977 Dec 09
PMID:Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin. 41 51

Immunoreactive GH release-inhibiting factor [somatostatin (SRIF)] was detected in hypothalamus, extrahypothalamic brain, pancreas, and stomach extracts of the rat, pigeon, tortoise, frog, teleost (cichlid), and elasmobranch (dogfish) and in the whole brain of the cyclostome (hagfish). The SRIF concentration was higher in the pancreas and gastrointestinal tract than in the hypothalamus and extrahypothalamic brain in most species. Extracts of the various tissues from the different species assayed in serial dilutions gave displacement curves parallel to those of synthetic mammalian SRIF. Cation exchange chromatography of hypothalamic extracts from the various species revealed two major immunoreactive peaks, one of which correpsonds to synthetic SRIF in elution volume, the other being less basic. Affinity chromatography-purified immunoreactive SRIF from frog brain, pancreas, and stomach extracts coeluted with synthetic SRIF in high pressure liquid chromatography. The results indicate that immunoreactive SRIF in various tissues and in different vertebrates is indistinguishable and suggest that there has been no change in the molecule during at least 400 million yr of evolution.
Endocrinology 1979 Dec
PMID:Phylogenetic and anatomical distribution of somatostatin in vertebrates. 49 75

Electrical stimulation of the preoptic area resulted in a significant increase in the secretion rate of immunoreactive somatostatin (IRS) and its concentration in the hypophysial portal blood of urethane-anesthetized rats. In contrast, stimulation of the ventromedial nucleus did not cause any changes in portal immunoreactive somatostatin. The flow rate of portal blood also increased significantly by electrical stimuli to the preoptic area but not to the ventromedial hypothalamus. These findings support the view that the preoptic area plays an inhibitory role in the regulation of GH secretion by increasing the release of somatostatin into hypophysial portal vessels in the rat.
Endocrinology 1979 Dec
PMID:Enhancement of immunoreactive somatostatin release into hypophysial portal blood by electrical stimulation of the preoptic area in the rat. 49 80

Polypeptides with somatostatin-like immunoreactivity (SLI) and approximate molecular weights of 12,000, 3,000, and 1,600 were isolated from acid extracts of the canine extrahypothalamic brain and stomach by affinity chromatography, ion exchange, gel filtration, and isoelectric focusing. The 12,000-dalton SLI was acidic, whereas the 3,000- and 1,600-dalton forms were basic molecules. All SLI fractions diluted proportionally in a RIA employing an antibody directed toward the central region of somatostatin. Like synthetic somatostatin, the 1,600-dalton SLI inhibited pentagastrin-stimulated gastric acid secretion in rats. Neither of the two larger forms of SLI were dissociated by 6 M guanidinium HCl. However, treatment with dithiothreitol, which reduces disulfide bonds, resulted in the conversion of a large portion of the 12,000-dalton SLI to the 1,600-dalton form. These data are compatible with a model of a 12,000-dalton SLI consisting of somatostatin bound to an acidic polypeptide by a peptide bond and a disulfide bond. Variations in the relative rates of hydrolysis of the peptide bonds and reduction of the disulfide bonds in different tissues may result in three forms of the 12,000-dalton polypeptide in which both bonds are intact or one of the two bonds is cleaved.
Endocrinology 1979 Dec
PMID:Properties of somatostatin-like immunoreactive polypeptides in the canine extrahypothalamic brain and stomach. 49 81

A pharmacological study was made of the effects of various muscarinic and nicotinic agonists and their antagonists on the release of [3H]noradrenaline ([3H]NA) from cultures of isolated bovine adrenal medullary cells. A study was also made of the effects of substance P and somatostatin on the release of [3H]NA evoked by nicotinic agonists. By 2 days in culture these adrenal 'paraneurons' had developed long varicose processes with growth cones and generally resembled noradrenergic neurons in culture. In the present study, adrenal paraneurons were incubated with [3H]NA which was taken up and stored in reserpine-sensitive sites. Exposure of the cultures to acetylcholine (ACh) resulted in release of [3H]NA into the external medium. High concentrations of K+ (56 mM) also evoked release of [3H]NA. The release of [3H]NA induced by ACh or K+ (56 mM) was Ca2+-dependent. Pharmacological studies with nicotinic (ACh, nicotine) and muscarinic (methacholine, pilocarpine) agonists and their antagonists (mecamylasmine, d-tubocurarine, hexamethonium; and atropine, scopolamine, respectively) showed that the adrenal paraneurons contained only nicotinic receptors. Substance P produced a dose-dependent inhibition of ACh (5 x 10(-5) M) stimulated [3H]NA release in the range of 10(-8) to 5 x 10(-5) M with an ID50 of 10(-6) M. A similar inhibition of NA release by substance P was obtained when nicotine (K X 10(-6) M) was used as the agonist, but not when K+ (50 MM) was used to depolarize the cells. Substance P (10-10) to 5 x 10(-5) M) by itself did not have a significant effect on the basal release rate of [3H]NA from these cells. Somatostatin at relatively high concentrations (10(-6)-10(-3) M; ID50 2 x 10(-5) M) inhibited the release induced by ACh, but not by K+ (56 mM). The present results provide the first direct evidence at a cellular level that substance P and somatostatin act as inhibitory modulators of the nicotinic ACh response, and support a role for these peptides as inhibitory neuromodulators at nicotinic receptor sites in the nervous system.
Brain Res 1979 Dec 14
PMID:Pharmacological characterization of adrenal paraneurons: substance P and somatostatin as inhibitory modulators of the nicotinic response. 50 17

An adenocarcinoma of the second portion of the duodenum in a 26-year-old male is presented. The patient was suffering from pain in the epigastrium. Immunofluorescent studies revealed that it consisted almost exclusively of cells with a distincly positive somatostatin-like immunoreactivity. Ultrastructurally, the cytoplasm of the tumor cells had numerous large round granules (about 400 micrometers) with variable electron density. Most of these cells closely resembled the D cells normally seen in the duodenum and the islets of the pancreas, although a few argyrophil cells could be demonstrated by light microscopy. Radioimmunoassay of extracts of the tumor revealed a large amount of somatostatin (2260 pg/mg); substance P and VIP were detected also. Somatostatinoma has been known to occur in the pancreas, but this seems to be the first somatostatinoma found in the intestine.
Cancer 1979 Dec
PMID:Somatostatinoma of the duodenum. 50 96

This dose-response study deals with the relative inhibitory effect of somatostatin on the acetylcholine-stimulated release of pancreatic polypeptide (PP), glucagon, and insulin from the isolated canine pancrease. Somatostatin in picomolar doses potently inhibited insulin and glucagon secretion, whereas PP secretion was relatively insensitive. Also, in the absence of acetylcholine, somatostatin exerted a preferential inhibition of the release insulin and glucagon compared with PP. These findings point to a physiologically important role of somatostatin for the secretion of insulin and glucagon, but probably not for PP.
Metabolism 1979 Dec
PMID:Differential sensitivity to somatostatin of pancreatic polypeptide, glucagon and insulin secretion from the isolated perfused canine pancreas. 51 83

The role of nerves that liberate vasoactive intestinal polypeptide (VIP) in the porcine pancrease as mediators of the atropine-resistant action of the vagus on flow and bicarbonate (HCO3) secretion was examined. Efferent electrical stimulation of the vagus in atropinized pigs produced a profuse flow of pancreatic juice with high HCO3 content concomitantly with a significant increase in pancreatic VIP output from 13 to 113 fmol/min. Intravenous administration of somatostatin (SRIF) during continuous electrical vagal stimulation caused a parallel suppression of the VIP release and the pancreatic fluid and HCO3 secretion to prestimulatory values. The SRIF-induced reduction in fluid and HCO3 secretion seemed to be mediated via an inhibition of the VIP release rather than through a direct effect on the exocrine cells, inasmuch as SRIF did not influence the VIP-provoked exocrine response from the in vitro isolated perfused porcine pancreas. The results support the view that VIP is transmitter in the vagally induced atropine-resistant water and HCO3 secretion from the porcine pancreas.
Am J Physiol 1979 Dec
PMID:Vasoactive intestinal polypeptide in vagally mediated pancreatic secretion of fluid and HCO3. 51 50


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>